General
Preferred name
dihydroergotamine
Synonyms
DIHYDROERGOTAMINE MESYLATE ()
DIHYDROERGOTAMINE TARTRATE ()
Dihydroergotamine methanesulfonate ()
Dihydroergotamine (mesylate) ()
NSC-759848 ()
Dihydroergotamine mesylate component of embolex ()
DIHYDERGOT ()
DIERGO ()
Dihydroergotamine mesilate ()
Dihydroergotamine Methanesulfonate ()
DHE-45 ()
TONOPAN ()
MIGRANAL ()
TRUDHESA ()
D.H.E. 45 ()
Neomigran ()
MAP-0004 ()
9,10-dihydroergotamine ()
Dihidroergotamina ()
MAP0004 ()
DIHYDROERGOTAMINE MESYLATE COMPONENT OF EMBOLEX ()
P&D ID
PD010104
CAS
6190-39-2
5989-77-5
1381-02-8
511-12-6
Tags
available
biased GPCR ligand
drug
Approved by
FDA
First approval
1946
Drug indication
migraine disorder
Migraine
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Dihydroergotamine mesylate is an ergot alkaloid that can be used for the research of migraines[1][2][3].
ROE The major excretory route of dihydroergotamine is via the bile in the feces. ; Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection.
DESCRIPTION Dihydroergotamine is an ergot alkaloid. It is used as a vasoconstrictor. The drug is administered as dihydroergotamine mesylate (PubChem CID 71171). The use of ergot alkaloids in the clinic has been discontinued or restricted due to their propensity to cause fibrosis. (GtoPdb)
DESCRIPTION Partial alpha agonist. Non-selective (Tocriscreen Plus)
DESCRIPTION Ergot alkaloid; vasoconstrictor; competitive serotonin receptor antagonist; partial agonist at alpha adrenoceptors and D2 dopamine receptors (LOPAC library)
DESCRIPTION Partial α agonist. Non-selective (Tocriscreen Total)
DESCRIPTION Muscarinic M3 antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Dihydroergotamine mesylate is a derivative of ergotamine and an agonist of the serotonin (5-HT) receptor. Dihydroergotamine mesylate have been used in the treatment of migraine headaches. (Enamine Bioactive Compounds)
Cell lines
0
Organisms
1
Compound Sets
32
BiasDB
Dihydroergotamine
Cayman Chemical Bioactives
23847
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1200517
CHEMBL1732
ChEMBL Drugs
CHEMBL1200517
CHEMBL1732
Concise Guide to Pharmacology 2017/18
121
Concise Guide to Pharmacology 2019/20
121
Concise Guide to Pharmacology 2021/22
121
Concise Guide to Pharmacology 2023/24
121
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00320
DrugBank Approved Drugs
DB00320
DrugCentral
888
DrugCentral Approved Drugs
888
DrugMAP
DM5IKUF
DrugMAP Approved Drugs
DM5IKUF
Enamine Bioactive Compounds
EBC-08683
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101404
EUbOPEN Chemogenomics Library
EUB0000895
Guide to Pharmacology
121
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1732
MedChem Express Bioactive Compound Library
HY-B0670A
NCATS Inxight Approved Drugs
436O5HM03C
NPC Screening Collection
Other bioactive compounds
Tocris Bioactive Compound Library
0475
Tocriscreen Plus
0475
Tocriscreen Total
ZINC Tool Compounds
ZINC000003978005
External IDs
69
Properties
(calculated by RDKit )
Molecular Weight
583.28
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
8
Aromatic Ring Count
3
cLogP
2.08
TPSA
118.21
Fraction CSP3
0.48
Chiral centers
7.0
Largest ring
6.0
QED
0.43
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
MOA
Adrenergic Receptor agonist
Adrenergic Receptor antagonist
Agonist
serotonin receptor agonist
Target
Serotonin 1d (5-HT1d) receptor
ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7
5-HT Receptor
Primary Target
Non-selective Adrenergic ? Receptors
Indication
migraine headache
Therapeutic Class
Antimigraine Agents
Pathway
GPCR/G protein
Neuronal Signaling
Recommended Cell Concentration
100 nM
Source data